Sichuan Hexie Shuangma Co., Ltd. Class A

Sichuan Hexie Shuangma Co., Ltd. Class A

SSZSE:000935
17.61
CNY
+0.33
(+1.91%)
19.92BMarket Cap
Oct 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.24
4.19
2.78
2.91
3.64
2.54
2.36
1.92
1.61
1.6
1.6
1.42
1.58
- -
Basic EPS, GAAP
0.11
0.17
-0.16
0.11
0.27
0.91
0.95
1.16
1.3
1.08
1.29
0.41
0.39
- -
Free Cash Flow per Basic Share
0.42
0.95
0.19
0.64
0.7
0.86
1.13
0.66
0.45
0.45
0.37
0.54
0.33
- -
Dividend per Share
0.1
0.23
0.2
0.09
0.12
0.24
- -
0.1
0.21
0.24
- -
0.35
0.03
0.03
Book Value per Share
3.27
4.16
3.45
3.56
3.83
4.56
5.51
6.63
7.75
8.51
9.75
9.79
10.18
10.15
Tangible Book Value per Share
2.8
3.52
2.95
3.08
3.34
4.35
5.32
6.57
7.63
8.39
9.64
8.42
8.84
8.82
Basic Weighted Avg Shares
622
610
711
769
754
764
767
766
761
764
764
755
765
752
Sales/Revenue/Turnover
2,017
2,553
1,975
2,238
2,748
1,940
1,810
1,473
1,224
1,220
1,219
1,075
1,206
- -
Operating Margin (%)
10.36
14.89
-0.52
8.57
14.96
43.03
42.34
38.86
34.57
27.91
38.99
33.27
17.63
- -
Depreciation Expense
193
229
229
235
230
93
77
64
51
64
68
81
128
- -
Net Income, GAAP
68
104
-114
85
204
696
729
889
989
825
985
309
298
- -
Effective Tax Rate (%)
17.58
18.72
- -
31.57
16.27
12.92
11.71
9.51
13.59
11.42
13.02
- -
14.72
- -
Profit Margin (%)
3.39
4.06
-5.76
3.78
7.41
35.87
40.25
60.35
80.79
67.66
80.82
28.79
24.74
- -
Working Capital
-251
-141
-1,069
-1,145
-1,532
864
631
1,277
924
363
1,142
285
501
376
LT Debt
6
688
356
- -
- -
- -
- -
10
12
9
5
610
963
1,010
Total Equity
3,436
3,917
3,266
3,324
3,579
3,485
4,212
5,081
5,937
6,516
7,459
7,553
7,851
7,826
Return on Invested Capital (%)
4.54
4.91
- -
1.49
5.42
16.48
18.34
16.72
17.77
13.19
14.01
- -
3.67
- -
Return on Capital (%)
-0.49
0.47
- -
2.59
4.95
17.06
18.65
19.12
18
13.33
14.2
- -
3.73
- -
Return on Common Equity (%)
3.46
4.54
-4.38
3.16
7.23
21.74
18.95
19.17
18.01
13.3
14.14
4.15
3.91
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
36
34
51
LT Borrowings
933
980
986
LT Finance Leases
31
31
24
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
763
763
763
Market Capitalization
18,964
19,063
19,918

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,116
1,148
1,114
Cash, Cash Equivalents & STI
561
583
596
Accounts Receivable, Net
91
113
99
Inventories
204
219
223
Total Current Liabilities
615
542
738
Payables & Accruals
- -
- -
- -
ST Debt
36
34
51
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.46%
9.26%
3.95%
Free Cash Flow
24.28%
-8.67%
-36.73%
Net Income, GAAP
17.68%
-11.61%
-3.59%
Sales/Revenue/Turnover
-3.55%
-3.39%
12.19%
Total Cash Common Dividend
2,427.52%
4,021.82%
-92.43%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
213
269
262
330
1,075
2025
325
304
- -
289
1,206
2026
267
265
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.14
0.17
0.09
0.41
2025
0.15
0.02
- -
0.01
0.39
2026
0.08
-0.11
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.28
- -
0.06
0.35
2025
0.01
0.01
- -
0.01
0.03
2026
0.01
0.01
- -
- -
- -

Company Description

CEO
Can Wen Huang
Full Time Employees
1,028
Sector
Non-energy minerals
Industry
Construction materials
Address
Office Building 1, Chengdu International Finance Center Chengdu SI China 610021
IPO Date
Aug 24, 1999
Business
Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) is a China-based company principally engaged in industrial investment management and private equity investment fund management; it manages assets encompassing building materials manufacturing, CNI biomedicine R&D and production, and private equity fund operations through its subsidiary Tibet Jinhe, which oversees funds totaling nearly CNY 28 billion invested in biomedical, advanced manufacturing, artificial intelligence, clean energy, self-driving cars, and other emerging sectors. The company produces and sells cement, commercial clinker, and aggregates for applications in roads, railways, airports, power stations, real estate, municipal infrastructure, and rural construction; through its acquired biomedicine assets, it offers peptide active pharmaceutical ingredients including GLP-1 drugs such as semaglutide, tirzepatide, and liraglutide, peptide contract development and manufacturing organization (CDMO) services, and cosmetic peptides. Founded in 1998 and headquartered in Chengdu, Sichuan Province, the company primarily operates in China with export activities to Southeast Asia and the Middle East; it was formerly known as Sichuan Shuangma Cement Co., Ltd. and changed its name in February 2022. In late 2024, Sichuan Hexie Shuangma completed the acquisition of 92.17% equity in Shenzhen Jianyuan Technology Co., Ltd. (also referred to as Shenzhen Jymed or Jian Yuan) for CNY 1.596 billion, marking its strategic entry into the biomedical sector; its controlling subsidiary Hubei Jianxiang obtained Russian GMP certification and completed construction of 10 peptide API production lines compliant with EU and FDA standards, with further capacity expansions underway.